home / stock / halo / halo articles
Saturday, Bristol Myers Squibb & Co (NYSE:BMY) released the first disclosure of data from the Phase 3 CheckMate -67T trial of the sub...
On Wednesday, for the first time, Halozyme Therapeutics Inc (NASDAQ:HALO) provided five-year financial guidance up to 2028. For...
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo&n...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire OCREVUS ® subcutaneous (SC) injection offers a new 10-minute administration with comparable effica...
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as...